Processa Pharmaceuticals
PCSA
7 hedge funds and large institutions have $5.07M invested in Processa Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.95% more ownership
Funds ownership: 0% → 4.95% (+5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Solas Capital Management
Darien,
Connecticut
|
+$2.5M |
| 2 |
Millennium Management
New York
|
+$594K |
| 3 |
Essex Investment Management
Boston,
Massachusetts
|
+$416K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$369K |
| 5 |
MYDA Advisors
Woodmere,
New York
|
+$222K |
Top Sellers
PCSA Hedge Fund Activity: Q4 2020 in Review
7 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2020, worth a combined $5.07M.
Buyers outnumbered sellers: 7 funds opened new PCSA positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Solas Capital Management, opening a new position worth an estimated $2.5M.
- 7 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $5.07M of Processa Pharmaceuticals stock for Q4 2020.
- 7 funds opened new Processa Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +7 holders.
- The largest Processa Pharmaceuticals buyer in Q4 2020 was Solas Capital Management, an estimated $2.5M added.
Based on aggregated 13F filings for Q4 2020.